_1662372170.png)
· Efficacy of Cervavax vaccine determined at RGCB lab
Thiruvananthapuram, Sep. 04: The Rajiv Gandhi Centre for Biotechnology (RGCB) is contributing significantly in determining the efficacy of Cervavax, India’s first indigenously developed vaccine for the prevention of cervical cancer, the second-most prevalent cancer among women in the country.
Union Science & Technology Minister Dr Jitendra Singh, who announced the scientific completion of the quadrivalent Human Papilloma Virus (qHPV) vaccine in New Delhi last week, said cervical cancer, though largely preventable, accounts for nearly one-fourth of the world’s cervical cancer deaths.
Current estimates indicate that every year approximately 1.25 lakh women are diagnosed with cervical cancer, and over 75, 000 die from the disease in India while 83 per cent of invasive cervical cancers are attributed to HPV 16 and HPV 18 in the country and 70 per cent of cases worldwide.
In the development of India’s first cervical cancer vaccine, the RGCB at Thiruvananthapuram has facilitated stringent tests in its state of the art laboratory to demonstrate the efficacy of Cervavax with infections as the endpoint.
“RGCB, as the scientific partner and stakeholder in this effort, has made significant contributions to the country’s determined efforts to eliminate cervical cancer,” its director Prof Chandrabhas Narayana said. “The RGCB laboratory for HPV testing facility is qualified as per international standards set by the WHO.”
At the launch function in the national capital, Dr Devasena Anantharaman, scientist who is heading the project at RGCB, was invited as an expert to discuss the current status of HPV diagnostics and the future directions for academic research in this area.
Dr Anantharaman said vaccination against HPV is the most effective intervention for preventing cervical cancer. “Vaccines mimic natural infections resulting in development of specific antibodies. In case of the qHPV vaccine also, the efficacy is measured by development of antibodies against each type of HPV present in the vaccine,” she pointed out.
“HPV vaccination is given to young adolescent girls, while HPV infections are acquired years later and cancer occurs due to persistent infections almost four decades since vaccination. Thus, one of the measures of vaccine efficacy is also to estimate HPV infection rates in those who are administered the vaccine. It is expected that, in case of the Cervavax, the rate of HPV 6, 11, 16 and 18 infections would be negligible in vaccinated individuals,” she explained.
The development of affordable and cost-effective cancer vaccine will go a long way in helping Indian women and women across the globe, and it comes close on the heels of India developing its first mRNA vaccine and intranasal vaccine against COVID-19.
Gurugram, India – October 11, 2023: Samsung announced exciting offers
Bangalore, 10th October 2023: The Nokia G42 5G (16GB+256G
Bengaluru, October 10, 2023 IN-SPACe (Indian National Space Promotion and
New Delhi, October 3, India- Philips India announces an exciting co
One of the largest CPG Pitch Slams in India, offering participants a chance to win one year of free access to NIQ data, valued at $30,000!<
 (1)_1713611592.jpg)
Through this exciting initiative, the brand aims to emerge as the go-to purveyor of authentic Chinese in India
New D
buy singulair 10mg without prescription buy montelukast 10mg online cheap cheap sildenafil online
Business / 29-04-2024
CSMIA's cargo operations thrive in FY 2024, driven by 10% rise in international volumesEducation / 29-04-2024
“69% Female Representation in MBA Analytics, Underscores the Evolving Landscape of Education – Sandeep Singh, Chairman BoG – IIM Kashipur”Business / 29-04-2024
NIQ Announces Inaugural ‘NIQ Founders Pitch Slam’ Competition for Emerging CPG Brands in Indiaeducation / 29-04-2024
IIT Kanpur is inviting applications for the 4th batch of eMasters degree program in Data Science and Business AnalyticsKerala / 29-04-2024
CII Digital Saksham Transforms Kerala's Entrepreneurial Landscape: Empowering Micro-Businesses for a Digital FuturePelikken © Copyright 2022, All Rights Reserved
